On Tuesday, Zealand Pharma secured a USD 50m option for potential acquisitions of products or companies in a financing agreement with private investment firm Oberland Capital.
However, with clinical trials underway and its goal of having five products on the market in 2025, Zealand Pharma is already well-armed in this business area, CEO at Zealand Pharma Emmanuel Dulac tells MedWatch. Funding from the option, which much be exercised before June 30, 2023, would likely be spent elsewhere.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Hearing firms urge FDA to increase OTC safety requirements
A number of the world’s biggest hearing aid manufacturers have come together to encourage the US health authority to tighten the safety requirements for OTC hearing aids, which will hit the shelves in the US sometime this year.
Novo Nordisk launches oral semaglutide in India
Novo Nordisk’s diabetes drug, semaglutide, will be sold in the country in a similar price range as its injectable version.
Coloplast initiates trial of ostomy leakage product
The medtech company will being clinically testing its ostomy add-on product, Heylo, in January.
Top news from MedWatch this week
Miss anything?
Danish bank cuts Genmab price target, retains "buy" recommendation
Jyske Bank has adjusted its valuation of Genmab’s share price target to DKK 2850 (USD 434.4). Investors should continue to buy, the Danish bank says.
QA Specialist 
Design Control Specialist / System Engineer 
Associate Director, GMP QA, Biologics/Radiopharmaceuticals 
Commercial Excellence Lead 
Associate Director, Tax 
Senior Key Account Manager 
KLIFO is looking for a Director, Business Support for our Glostrup office 
GxP QA Compliance Manager for Quality Assurance 
Director Medical Science 
Senior HR Director, HR Denmark, Ferring 
Senior Scientist 
Senior Director, Global Regulatory Lead 
NORDIC Medical Sales Director 
Health Economist 
Chemists are wanted for ALK's internal Aircraft Corps